Search results for "610"

showing 10 items of 1353 documents

Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial.

2014

Importance The disease process leading to clinical type 1 diabetes often starts during the first years of life. Early exposure to complex dietary proteins may increase the risk of β-cell autoimmunity in children at genetic risk for type 1 diabetes. Extensively hydrolyzed formulas do not contain intact proteins. Objective To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of diabetes-associated autoantibodies in young children. Design, Setting, and Participants A double-blind randomized clinical trial of 2159 infants with HLA-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to Ja…

Maleinsulin-Secreting CellsautoantibodiesAutoimmunity2700 General MedicineGastroenterologylaw.invention0302 clinical medicineRandomized controlled trialnewbornlawCaseindouble-blind methodCumulative incidence030212 general & internal medicinehumans: Multidisciplinary general & others [D99] [Human health sciences]childHazard ratioGeneral Medicinefollow-up studiesInfant Formulaanimalscaseinstype 1femaleMilkbreast feedinghydrolysisdiabetes mellitusRiskmedicine.medical_specialty: Multidisciplinaire généralités & autres [D99] [Sciences de la santé humaine]β-cell autoimmunity610 Medicine & health030209 endocrinology & metabolismWeaningArticlehydrolyzed infant formula03 medical and health sciencesInternal medicineDiabetes mellitusHydrolyzed infant formula and early β-cell autoimmunitymedicineanimals; autoantibodies; breast feeding; caseins; child; diabetes mellitus; type 1; dietary proteins; double-blind method; female; follow-up studies; humans; hydrolysis; incidence; infant; newborn; insulin-Secreting Cells; Male; Milk; Risk; Weaning; Autoimmunity; Infant FormulaType 1 diabetesbusiness.industrydietary proteinsta1183Infant Newbornmedicine.diseaseta3123infantDiabetes Mellitus Type 1EndocrinologyInfant formula10036 Medical ClinicincidencebusinessBreast feeding
researchProduct

Eliminating Factor H-Binding Activity of Borrelia burgdorferi CspZ Combined with Virus-Like Particle Conjugation Enhances Its Efficacy as a Lyme Dise…

2018

The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the most common tick-borne disease in the U.S and Europe. No potent human vaccine is currently available. The innate immune complement system is vital to host defense against pathogens, as complement activation on the surface of spirochetes results in bacterial killing. Complement system is inhibited by the complement regulator factor H. To escape killing, B. burgdorferi produces an outer surface protein CspZ that binds factor H to inhibit complement activation on the cell surface. Immunization with CspZ alone does not protect mice from infection, which we speculate is because factor H-binding cloaks potentially pro…

Malelcsh:Immunologic diseases. Allergy0301 basic medicine030106 microbiologyImmunologySerum Bactericidal Antibody Assayvirus-like particlesEpitopeMicrobiologyMice03 medical and health sciencesAntigenvaccineBorreliaAnimalsLyme diseaseImmunology and AllergyVaccines Virus-Like Particleddc:610Borrelia burgdorferiOriginal ResearchInnate immune systembiologyBorreliaImmunogenicityImmunization PassiveLyme Disease Vaccinesfactor Hbiology.organism_classificationAntibodies Bacterial3. Good healthComplement systemCspZ030104 developmental biologyBorrelia burgdorferiComplement Factor Hbiology.proteinAntibodylcsh:RC581-607Bacterial Outer Membrane ProteinsFrontiers in Immunology
researchProduct

Molecular evidence of HLA-B27 in a historical case of ankylosing spondylitis

2005

Malemedicine.medical_specialty10017 Institute of Anatomy2745 RheumatologyImmunologyMEDLINEMolecular evidence610 Medicine & healthPolymerase Chain ReactionHistory 17th CenturyRheumatologyInternal medicinemedicineHumans2736 Pharmacology (medical)Immunology and AllergySpondylitis AnkylosingPharmacology (medical)SpondylitisHLA-B27 AntigenHLA-B27Ankylosing spondylitis2403 Immunologybusiness.industrymedicine.diseaseDermatologyRheumatologyHistory 16th CenturyAnthropologyImmunology11294 Institute of Evolutionary Medicine2723 Immunology and Allergy570 Life sciences; biologybusiness
researchProduct

Non‐Pharmacologic Multicomponent Interventions Preventing Delirium in Hospitalized People

2020

BACKGROUND/OBJECTIVES Delirium is a common neurobehavioral complication in hospitalized patients with a high prevalence in various clinical settings. Prevention of delirium is critical due to its common occurrence and associated poor outcomes. Our objective was to evaluate the efficacy of multicomponent interventions in preventing incident delirium in hospitalized patients at risk. DESIGN Systematic review and meta-analysis. SETTING Hospital. PARTICIPANTS We included a study if it was a randomized controlled trial and was evaluating effects of coordinated non-pharmacologic multicomponent interventions in the prevention of delirium. MEASUREMENTS We performed a systematic literature search in…

Malemedicine.medical_specialty610 Medizinmulticomponent interventions ; delirium ; prevention ; non-pharmacologic interventionslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallaw610 Medical sciencesOutcome Assessment Health Caremental disordersmedicineHumans030212 general & internal medicineAgedRandomized Controlled Trials as TopicAged 80 and overInpatientsInpatient mortalitybusiness.industryIncidenceIncidence (epidemiology)Multicomponent interventionsDeliriumMiddle AgedAccidentalEmergency medicineDeliriumFemalePreventive MedicineGeriatrics and Gerontologymedicine.symptomComplicationbusiness030217 neurology & neurosurgeryIndependent livingJournal of the American Geriatrics Society
researchProduct

Mortality rates and risk factors for emergent open repair of abdominal aortic aneurysms in the endovascular era

2018

The background of this paper is to report the mortality at 30 and 90 days and at mean follow-up after open abdominal aortic aneurysms (AAA) emergent repair and to identify predictive risk factors for 30- and 90-day mortality. Between 1997 and 2002, 104 patients underwent emergent AAA open surgery. Symptomatic and ruptured AAAs were observed, respectively, in 21 and 79% of cases. Mean patient age was 70 (SD 9.2) years. Mean aneurysm maximal diameter was 7.4 (SD 1.6) cm. Primary endpoints were 30- and 90-day mortality. Significant mortality-related risk factor identification was the secondary endpoint. Open repair trend and its related perioperative mortality with a per-year analysis and a co…

Malemedicine.medical_specialtyAbdominal compartment syndromemedicine.medical_treatment610 Medicine & healthSymptomatic030204 cardiovascular system & hematologySettore MED/22 - Chirurgia VascolareEndovascular aneurysm repairEndovascular aneurysm repair03 medical and health sciences0302 clinical medicineAneurysmRisk FactorsmedicineHumansMortalityRisk factorAgedRetrospective Studiesbusiness.industryOpen repairMortality rateEndovascular Procedures10060 Epidemiology Biostatistics and Prevention Institute (EBPI)PerioperativeMiddle Agedmedicine.diseaseSurvival AnalysisRupturedAbdominal aortic aneurysm10020 Clinic for Cardiac Surgery2746 SurgerySurgeryTreatment Outcome030220 oncology & carcinogenesisAbdominal aortic aneurysmFemaleVascular GraftingSurgeryEmergenciesbusinessAortic Aneurysm AbdominalFollow-Up StudiesAbdominal surgeryUpdates in Surgery
researchProduct

Low Homoarginine Levels in the Prognosis of Patients With Acute Chest Pain.

2016

Background The endogenous amino acid homoarginine predicts mortality in cerebro‐ and cardiovascular disease. The objective was to explore whether homoarginine is associated with atrial fibrillation ( AF ) and outcome in patients with acute chest pain. Methods and Results One thousand six hundred forty‐nine patients with acute chest pain were consecutively enrolled in this study, of whom 589 were diagnosed acute coronary syndrome ( ACS ). On admission, plasma concentrations of homoarginine as well as brain natriuretic peptide ( BNP ), and high‐sensitivity assayed troponin I (hsTnI) were determined along with electrocardiography ( ECG ) variables. During a median follow‐up of 183 days, 60 ma…

Malemedicine.medical_specialtyAcute coronary syndromeChest PainMyocardial InfarctionKaplan-Meier Estimate030204 cardiovascular system & hematologyChest painacute coronary syndrome03 medical and health sciences0302 clinical medicineInternal medicineTroponin IAtrial FibrillationNatriuretic Peptide BrainmedicineHumansCoronary Heart Disease030212 general & internal medicineMyocardial infarctionddc:610AgedProportional Hazards ModelsOriginal Researchbusiness.industryHazard ratioAtrial fibrillationMiddle Agedmedicine.diseaseBrain natriuretic peptidePrognosisAcute PainHomoarginine3. Good healthSurgeryStrokel‐arginine:glycine amidinotransferaseCardiologyEndothelium/Vascular Type/Nitric OxideFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessAcute Coronary SyndromesMaceBiomarkersJournal of the American Heart Association
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)

2012

Abstract Introduction Common symptoms for children with Anderson-Fabry Disease (FD) such as acroparaesthesia and gastrointestinal manifestations can only be objectively assessed in patients using a valid instrument. To date, no such instrument exists. Methods A preliminary 40-item measure of symptoms and experience with FD, the Fabry-specific Paediatric Health and Pain Questionnaire (FPHPQ) was developed, but lacked a formal assessment of its measurement properties. The FPHPQ was used in the Fabry Outcome Survey (FOS), a registry for all patients with a confirmed diagnosis of FD who are receiving agalsidase alfa, or are treatment naïve and who are managed by physicians participating in FOS.…

Malemedicine.medical_specialtyAdolescentIntraclass correlation610 Medicine & healthlcsh:Computer applications to medicine. Medical informaticsSeverity of Illness IndexPsychometrics validationCronbach's alphaQuality of lifeSurveys and QuestionnairesSeverity of illnessmedicineHumansBrief Pain InventoryChildChildrenPain MeasurementFabry diseaseItem analysisbusiness.industryResearchPublic Health Environmental and Occupational HealthReproducibility of ResultsConstruct validity2739 Public Health Environmental and Occupational HealthGeneral MedicinePaediatric Health and Pain Questionnairemedicine.diseaseFabry disease10036 Medical ClinicChild PreschoolEnzyme replacement therapyQuality of LifePhysical therapylcsh:R858-859.7FemalebusinessHealth and Quality of Life Outcomes
researchProduct

Less invasive (common) femoral artery aneurysm repair using endografts and limited dissection

2013

Objective We report our experience with the treatment of femoral artery aneurysms (FAAs) under local anaesthesia with limited dissection, using endografts to facilitate the proximal anastomosis and some distal anastomoses. Method Between January 2006 and December 2010, six males, mean age 72 years (range, 65–80 years) with FAAs were treated at the University Hospital of Zurich. All operations were performed under local anaesthesia with analgosedation, except for one performed under spinal anaesthesia. After limited dissection and puncture of the anterior wall of the FAA, a sheath and a self-expanding endograft were introduced over a guide wire and with fluoroscopy they were guided intralumi…

Malemedicine.medical_specialtyAnastomosismedicine.medical_treatmentEndograft610 Medicine & healthFemoral arteryDissection (medical)AnastomosisSettore MED/22 - Chirurgia Vascolare2705 Cardiology and Cardiovascular MedicineAneurysmmedicine.arteryDeep Femoral ArteryHumansMedicineAgedMedicine(all)Aged 80 and over10042 Clinic for Diagnostic and Interventional Radiologybusiness.industryEndovascular ProceduresBalloon catheterExternal iliac arteryStentmedicine.diseaseAneurysmBlood Vessel Prosthesis10020 Clinic for Cardiac Surgery2746 SurgerySurgeryFemoral ArteryCommon femoral arteryFemaleSurgeryRadiologyCardiology and Cardiovascular MedicinebusinessCommon femoral artery Aneurysm Endograft Anastomosis
researchProduct

Venous thromboembolism in patients hospitalized for hip joint replacement surgery

2020

Venous thromboembolism (VTE) is a potentially life-threatening disease. Major transient risk factors include trauma, surgery, and immobilization. Patients undergoing hip joint replacement (HJR) are characterized by a high risk of postoperative VTE, but data on the time trends of VTE rates in this population are sparse.In an analysis of the German nationwide inpatient sample, we included all hospitalizations for elective primary HJR in Germany from 2005 to 2016. Time trends of the surgical procedure, overall death rates, and VTE rates were analysed, and predictors of VTE identified.Overall, 1,885,839 inpatients with elective primary HJR (59.1% women, 51.4% ≥70 years) were included in the ana…

Malemedicine.medical_specialtyArthroplasty Replacement HipPopulation2720 Hematology610 Medicine & healthDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsHip replacementGermanymedicineHumanscardiovascular diseasesHospital Mortalityeducationeducation.field_of_studybusiness.industryMortality rate10031 Clinic for AngiologyCancerPerioperativeVenous ThromboembolismHematologyequipment and suppliesmedicine.diseaseSurgeryPulmonary embolismHospitalization030220 oncology & carcinogenesisFemalebusinessVenous thromboembolism
researchProduct